

Jens Benn Sørensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1331388/publications.pdf>

Version: 2024-02-01

30
papers

572
citations

933447

10
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

1038
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.	3.7	124
2	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 569-580.	10.7	117
3	Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 418-430.	2.8	57
4	Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. <i>Oncotarget</i> , 2018, 9, 26195-26208.	1.8	35
5	Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. <i>Anticancer Research</i> , 2015, 35, 6223-9.	1.1	30
6	Intratour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 2494-2503.	2.8	28
7	Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages Iâ€”III A. <i>European Respiratory Review</i> , 2015, 24, 340-355.	7.1	27
8	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2847.	4.1	25
9	Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. <i>Lung Cancer</i> , 2017, 113, 14-17.	2.0	20
10	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€”Real World Efficacy. <i>Cancers</i> , 2021, 13, 4846.	3.7	19
11	Are differentially expressed microRNA<sc>s useful in the diagnostics of malignant pleural mesothelioma?. <i>Apmis</i> , 2012, 120, 767-769.	2.0	11
12	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. <i>Acta OncolÃ³gica</i> , 2022, 61, 409-416.	1.8	11
13	Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)â€”validation in two independent cohorts. <i>PLoS ONE</i> , 2018, 13, e0194609.	2.5	9
14	Implementation of lung cancer CT screening in the Nordic countries. <i>Acta OncolÃ³gica</i> , 2017, 56, 1249-1257.	1.8	9
15	Development of Syndrome of Inappropriate Secretion of Antidiuretic Hormone During Progression of Metastatic Breast Cancer. <i>Acta OncolÃ³gica</i> , 1997, 36, 535-537.	1.8	7
16	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Nonâ€”Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2022, , .	3.0	7
17	Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100165.	1.1	6
18	Phase II study of 4?-iodo-4?-deoxydoxorubicin in non-resectable non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 399-402.	2.3	5

#	ARTICLE	IF	CITATIONS
19	Very Early Response Evaluation by PET/MR in Patients with Lung Cancer – Timing and Feasibility. <i>Diagnostics</i> , 2019, 9, 35.	2.6	5
20	Phase II study of teniposide in adenocarcinoma of the lung. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 487-489.	2.3	4
21	Use of TUBB3 for patient stratification and prognosis in lung cancer. <i>Lung Cancer Management</i> , 2015, 4, 97-110.	1.5	4
22	The prevalence of <i>ALK</i> rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. <i>Histopathology</i> , 2017, 70, 889-895.	2.9	3
23	Long-term Oncologic and Financial Implications of Lung Cancer Screening. <i>Thoracic Surgery Clinics</i> , 2015, 25, 223-229.	1.0	2
24	Treatment Algorithm for Advanced <i>ALK</i> -Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e156-e157.	1.1	2
25	Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005 – 2015): SCAN-LEAF study. <i>Future Oncology</i> , 2021, , .	2.4	2
26	Correlation of <i>MET</i> -Receptor Overexpression with <i>MET</i> Gene Amplification and Patient Outcome in Malignant Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12868.	4.1	2
27	Syndrome of Inappropriate Antidiuresis in Small-Cell Lung Cancer. <i>Acta Medica Scandinavica</i> , 1987, 222, 155-161.	0.0	1
28	¹⁸ F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e351-e352.	1.3	0
29	Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e18502-e18502.	1.6	0
30	Abstract 2276: High frequency of pathogenic germline variants in patients with malignant mesothelioma. <i>Cancer Research</i> , 2022, 82, 2276-2276.	0.9	0